These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17125403)

  • 41. High throughput solubility measurement in drug discovery and development.
    Alsenz J; Kansy M
    Adv Drug Deliv Rev; 2007 Jul; 59(7):546-67. PubMed ID: 17604872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.
    Harper TW; Brassil PJ
    AAPS J; 2008; 10(1):200-7. PubMed ID: 18446520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs.
    Wolfson W
    Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292
    [No Abstract]   [Full Text] [Related]  

  • 45. [Application and development of in vitro metabolism study at early drug discovery stage].
    Wu H; Peng Y; Sun JG; Zhang XY; Zhong YX; Wang GJ
    Yao Xue Xue Bao; 2013 Jul; 48(7):1071-9. PubMed ID: 24133972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In silico predictions of ADME/T properties: progress and challenge.
    Hou T
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):306. PubMed ID: 21470177
    [No Abstract]   [Full Text] [Related]  

  • 47. Active pharmaceutical ingredient (API) production involving continuous processes--a process system engineering (PSE)-assisted design framework.
    Cervera-Padrell AE; Skovby T; Kiil S; Gani R; Gernaey KV
    Eur J Pharm Biopharm; 2012 Oct; 82(2):437-56. PubMed ID: 22820647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous flow technology vs. the batch-by-batch approach to produce pharmaceutical compounds.
    Cole KP; Johnson MD
    Expert Rev Clin Pharmacol; 2018 Jan; 11(1):5-13. PubMed ID: 29206489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drugs in liver disease.
    Branch RA
    Clin Pharmacol Ther; 1998 Oct; 64(4):462-5. PubMed ID: 9797803
    [No Abstract]   [Full Text] [Related]  

  • 50. Supercritical fluid technology: a promising approach in pharmaceutical research.
    Girotra P; Singh SK; Nagpal K
    Pharm Dev Technol; 2013 Feb; 18(1):22-38. PubMed ID: 23036159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools.
    Willmann S; Lippert J; Schmitt W
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):159-68. PubMed ID: 16922658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity.
    Guengerich FP
    Toxicol Lett; 1994 Feb; 70(2):133-8. PubMed ID: 8296317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of the near-infrared spectroscopy in the pharmaceutical technology.
    Jamrógiewicz M
    J Pharm Biomed Anal; 2012 Jul; 66():1-10. PubMed ID: 22469433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
    Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
    Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel fluorescent proteins for high-content screening.
    Wolff M; Wiedenmann J; Nienhaus GU; Valler M; Heilker R
    Drug Discov Today; 2006 Dec; 11(23-24):1054-60. PubMed ID: 17129823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there a best strategy for drug discovery?
    Warne P; Page C
    Drug News Perspect; 2003 Apr; 16(3):177-82. PubMed ID: 12819816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HTS technologies in biopharmaceutical discovery.
    Wu G; Doberstein SK
    Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.